Cell & Gene: The Podcast
76 episodes - English - Latest episode: 9 days ago - ★★★★★ - 35 ratingsCell & Gene, the most valuable online resource for delivering in-depth content from authoritative authors and sources to professionals in the CGT sector, introduces Cell & Gene: The Podcast. In each episode, Cell & Gene Chief Editor, Erin Harris, will talk to industry and academic leaders about their current initiatives and how they are moving the sector forward.
Homepage Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
Episodes
Moving to an Allogeneic RNA Cell Therapy Program with Cartesian Therapeutics' Dr. Metin Kurtoglu
May 26, 2022 08:00 - 19 minutes - 13.7 MBDr. Metin Kurtoglu, COO at Cartesian Therapeutics, explains the clinical-stage biotech's autologous RNA cell therapies, Descartes-08 for Myasthenia Gravis and Descartes-11 for multiple myeloma. He also explains Descartes-25, their allogeneic RNA cell therapy and the reasons for the move to "off-the-shelf," and why the future of RNA cell therapy is not confined to rare and fatal diseases. We also discuss post-care for patients having received infusions.
Gene Therapy's Commercial Manufacturing Issues with Encoded Therapeutics' Andy Stober
May 12, 2022 08:00 - 26 minutes - 18.5 MBEncoded Therapeutics' Chief Manufacturing Officer Andy Stober explains the unique commercial manufacturing issues in gene therapy and how to address them. Stober also shares some of the lessons he's learned, which may educate the next generation of gene therapy scientists to accelerate future manufacturing success. We also talk about what developers need to consider regarding the ethical responsibilities in gene therapy.
Inside CAR-T Therapy For Ovarian Cancer with Anixa Biosciences' Amit Kumar, Ph.D.
April 28, 2022 08:00 - 18 minutes - 12.9 MBAmit Kumar, Ph.D., President and CEO at Anixa Biosciences details the company’s progress on its Phase 1 trial for ovarian cancer. We also discuss why the company’s ovarian cancer program is integral for initial proof of concept for other solid tumor indications. He covers why CAR-T therapy uses an existing hormone/hormone receptor relationship to create a targeted approach to treat ovarian cancer. Dr. Kumar shares how the field of cell therapy may evolve in the short term, and much more.
Pivoting to Allogeneic CAR-T Therapies with Celyad Oncology’s CMO, Dr. Charlie Morris
April 14, 2022 08:00 - 25 minutes - 17.5 MBCelyad Oncology’s CMO, Dr. Charlie Morris, shares the benefits and challenges of the allogeneic approach versus the autologous approach and why a non-gene edited shRNA approach may result in better efficacy and safety for CAR-T therapies.
Rocket Pharmaceuticals' CEO Dr. Gaurav Shah on FDA's Clinical Holds on Gene Therapy Trials
March 31, 2022 08:00 - 26 minutes - 18.5 MBRocket Pharmaceuticals CEO Dr. Gaurav Shah offers his take on why gene therapy developers have been plagued by clinical holds, whether the FDA’s AAV-focused CTGTAC meeting's takeaways will hold up throughout 2022, and more.
Inside Solid Tumor Therapies with BlueSphere Bio’s CEO Dr. David Apelian
March 17, 2022 17:00 - 25 minutes - 17.3 MBBlueSphere Bio's CEO Dr. David Apelian explains the difficulties associated with treating solid tumor cancers as well as what the CGT sector needs to get right in the short term and why.
Restoration of Immune Balance with Anish Suri, Ph.D., President and CSO at Cue Biopharma
March 03, 2022 09:00 - 18 minutes - 13 MBCue Biopharma's Anish Suri, Ph.D., explains why the clinical-stage biopharma is engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the body to transform the treatment of cancer.
REGENXBIO's Nina Hunter, Ph.D. Details the Accelerated Approval Pathway for Gene Therapies
February 17, 2022 09:00 - 17 minutes - 12.3 MBREGENXBIO's VP of Regulatory and Science Policy, Nina Hunter, Ph.D., shares potential solutions to gene therapies' regulatory roadblocks and why the accelerated approval pathway is so pertinent.
Selecta Biosciences' Dr. Carsten Brunn on Gene Therapy with AAV Vectors
February 03, 2022 09:00 - 20 minutes - 14.5 MBSelecta Biosciences' President and CEO Dr. Carsten Brunn details the company's ImmTOR platform, which can mitigate unwanted immune responses that cause immune-related toxicities that impose significant treatment challenges with current therapies.
Cellevolve Bio's Dr. Derrell Porter on the Need for Diversity and Inclusion in Biotech
January 20, 2022 09:00 - 32 minutes - 22.5 MBCellevolve Bio's founder and CEO. Dr. Derrell Porter shares his experience with starting up a cell therapy company and why we, as an industry, need to advocate for more Black leaders and leaders of color in the biotech industry.
RNA's Advantages Over Other Cell Therapies with Cartesian's CSO
January 06, 2022 09:00 - 19 minutes - 13.7 MBDr. Michael Singer, CSO at Cartesian Therapeutics, details why RNA has advantages over other cell therapies, the company's three RNA trials, and the therapeutic benefit of multiple modifications.
Vor Biopharma's CEO on Genome Engineering of Hematopoietic Stem Cells
December 22, 2021 09:00 - 19 minutes - 13.2 MBVor Biopharma's CEO Dr. Robert Ang explains the company's lead engineered hematopoietic cell (eHSC) product candidate, genome engineering of HSCs, and the cell manufacturing process needed to leverage genome engineering technologies for the cells they're creating.
AVROBIO on Patient Advocacy's Role in Clinical Trial Development & Recruitment
December 09, 2021 09:00 - 28 minutes - 19.4 MBFernanda Copeland, Global Head, Patient Advocacy & Engagement at AVROBIO, explains how to incorporate community education, patient feedback, and more to improve clinical trial development and recruitment.
Understanding CAR-M Technology with Carisma Therapeutics' Dr. Debora Barton
November 24, 2021 09:00 - 19 minutes - 13.2 MBCarisma Therapeutics’ Dr. Barton breaks down the latest in CAR-M technology as well as the company's Phase 1 First-in-Human Study of Adenovirally Transduced Anti-HER2 CAR Macrophages in Subjects with HER2 Overexpressing Solid Tumors.
Inside the Gene Therapy for Coronary Artery Disease with XyloCor Therapeutics' Albert Gianchetti
November 11, 2021 09:00 - 15 minutes - 10.6 MBXyloCor Therapeutics' EXACT clinical trial is a Phase 1/2 multicenter, open-label, single arm, dose escalation trial for coronary artery disease — the most common type of heart disease — with gene therapy at its center.
Inside the Gene Therapy for Coronary Artery Disease with XyloCor Therapeutics' Albert Gianchetti
November 11, 2021 09:00 - 15 minutes - 10.6 MBXyloCor Therapeutics' EXACT clinical trial is a Phase 1/2 multicenter, open-label, single arm, dose escalation trial for coronary artery disease — the most common type of heart disease — with gene therapy at its center.
Advancing Patient Engagement with Novartis Gene Therapies' Dr. Amy Nicole Nayar
October 28, 2021 08:00 - 24 minutes - 16.9 MBDr. Amy Nicole Nayar, VP of US Patient Advocacy and Government Affairs at Novartis Gene Therapies explains what patient engagement should encompass in the cell and gene field as well as the unique challenges cell and gene therapy companies face where a patient engagement officer provides essential help.
BridgeBio's Approach to Gene Therapy & Nearing the Clinic
October 14, 2021 08:00 - 24 minutes - 16.9 MBBridgeBio's CEO of Gene Therapy, Dr. Eric David, explains the company's gene therapy programs for Canavan disease and congenital adrenal hyperplasia, their manufacturing plans, and the platform underpinning their novel approach to gene therapy.
Inside Spark Therapeutics' Investigational SPK-8011 for Hemophilia A
September 30, 2021 08:00 - 19 minutes - 13.5 MBSpark Therapeutics' Clinical Development Lead, Hematology, Dr. Tiffany Chang explains the company's data from its ongoing Phase 1/2 clinical trial of investigational SPK-8011 for hemophilia A, the largest gene therapy trial in this disease to date as well as the misconceptions and unknowns about the disease.
Gene Therapies for Spinal Cord-Related Disorders with SwanBio's CEO
September 16, 2021 09:00 - 20 minutes - 14 MBKaren Kozarsky, Ph.D., Co-Founder and CSO of SwanBio, explains how the company is pioneering a deep and varied pipeline of gene therapies for genetically defined neurological diseases with a focus on the spinal cord.
Chronic Lymphocytic Leukemia: A Patient's Perspective
September 02, 2021 12:00 - 31 minutes - 21.8 MBBob Levis was diagnosed with Chronic Lymphocytic Leukemia in 2002 and was one of the early experimental trial participants at Penn Medicine for Dr. Carl June’s CAR-T therapy. Bob shares his remarkable journey with CLL as well as his important work with the CLL Society.
State-of-the-Art GMP Manufacturing RNA Cell Therapies with Cartesian's CEO
August 19, 2021 09:00 - 25 minutes - 17.8 MBDr. Murat Kalayoglu, CEO at Cartesian Therapeutics, details the cell and gene therapy sector’s advancements in RNA cell therapy and the why behind the company's decision to build its own wholly-owned GMP manufacturing facility.
Therapeutic Firsts and "Eds and Meds" with Penn’s Dr. Bruce Levine
August 05, 2021 12:00 - 31 minutes - 21.8 MBUniversity of Pennsylvania’s Dr. Bruce Levine explains his road to adoptive immunotherapy trials, overcoming the gap between academia and industry, and how Philadelphia earned the "Cellicon Valley" name for its continued innovation in cell and gene therapy — and more.
Hospitals And Advanced Therapies with Penn Medicine’s Kevin Mahoney
July 22, 2021 10:00 - 30 minutes - 20.9 MBIn this episode of Cell & Gene: The Podcast, University of Pennsylvania Health System’s CEO Kevin Mahoney talks to Host Erin Harris about how hospital systems must evolve to meet the needs of cell and gene therapy patients as these complex therapies are commercialized. They discuss what comprises UPHS and the ongoing innovation it brings to advanced therapies as well as how the Health System stays patient-focused at all costs.
Enzyvant's Rachelle Jacques on the Biotech’s Lead Asset
July 08, 2021 12:00 - 24 minutes - 16.7 MBDuring this first episode of Cell & Gene: The Podcast, Host Erin Harris talks to Enzyvant’s CEO Rachelle Jacques about the biotech’s lead asset, investigational regenerative therapy RVT-802 for congenital athymia. Jacques provides an update on FDA approval and details what’s next for RVT-802. She explains tissue-based therapies — how far they’ve come and the work that’s left to be done. And, they discuss what being patient-focused means in the world of rare diseases.
Introducing Cell & Gene: The Podcast
June 30, 2021 12:00 - 1 minute - 1.07 MBCell & Gene, the online resource that delivers in-depth content from authoritative authors and sources to professionals in the CGT sector, is thrilled to introduce “Cell & Gene: The Podcast.” Cell and gene therapies offer huge potential to treat a wide range of diseases and their possibilities represent a new era in medicine. “Cell & Gene: The Podcast” will explore approved and pipeline therapies, new trends in manufacturing, the long, regulated road to commercialization, and everything in b...